Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

Barraclough, Allison; England, James T; Villa, Diego; Wight, Joel; Hapgood, Greg; Conn, Jason; Doo, Nicole Wong; Li, Eric Wenlong; Gilbertson, Michael; Shaw, Briony; Bishton, Mark J; Saeed, Malik; Ratnasingam, Sumita; Abeyakoon, Chathuri; Chong, Geoff; Wai, Shin Hnin; Ku, Matthew; Lee, Hui-Peng; Fleming, Kathryn; Tam, Constantine; Douglas, Genevieve; Cheah, Chan Y; Ng, Zi Yun; Rolfe, Tukten; Mills, Anthony K; Hamad, Nada; Cashman, Helen; Gleeson, Mary; Narayana, Manjunath; Hawkes, Eliza A

doi:10.3324/haematol.2022.281375

All Outputs (9)

Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline (2023)
Journal Article

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any a... Read More about Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom (2023)
Journal Article

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about... Read More about Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article

PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Incidence and Survival in Patients With Enteropathy-associated T-Cell Lymphoma: Nationwide Registry Studies From England and Denmark (2023)
Journal Article

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.

Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing (2023)
Journal Article

Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different t... Read More about Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing.

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance (2023)
Journal Article

Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between ‘low-grade’ (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics a... Read More about Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.